There are currently 298 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
NCT06274047
Recruiting
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Register for Updates
Micro-UltraSound In Cancer - Active Surveillance
NCT05558241
Recruiting
This study will compare the two imaging modalities (MRI and micro-ultrasound) during Active Surveillance of prostate cancer (PCa). Progression to clinically significant PCa will be assessed by first taking micro-US targeted samples (while blinded to MRI results), followed by MRI targeted samples, finishing with 12 systematic biopsy cores. The primary goal is to compare microUS to MRI for the detection of ≥GG2 PCa at confirmatory biopsy. This study will also collect blood samples from participant... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of California Los Angeles, Department of Urology, Los Angeles, California +3 locations
Conditions: Prostate Cancer
Register for Updates
Researching the Effect of Exercise on Cancer
NCT04589468
Recruiting
Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA l... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Natera, Inc. (Data or Specimen Analysis Only), San Carlos, California +7 locations
Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer
Register for Updates
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
NCT06817668
Recruiting
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Prostate Cancer
Register for Updates
Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
NCT05882253
Recruiting
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
Gender:
MALE
Ages:
All
Trial Updated:
05/13/2025
Locations: Audie Murphie VA, San Antonio, Texas +2 locations
Conditions: Prostate Cancer
Register for Updates
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT05751941
Recruiting
This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the treatment of participants with asymptomatic metastatic castration resistant prostate cancer (mCRPC) and no visceral metastases would enhance the activation of antigen presenting cells (APC) by sipuleucel-T.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Prostate Cancer, Metastatic Prostate Cancer
Register for Updates
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
NCT06972628
Recruiting
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan. Pluvicto is FDA-approved, but patients with super scan bone scans were previously excluded from the VISION clinical trial, leaving a knowledge gap. The study will enroll up to 30 men with metastatic castration-resistant prostate cance... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Excel Diagnostics & Nuclear Oncology Center, Houston, Texas
Conditions: Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis, Prostate Cancer (CRPC), Prostate Cancer, Prostate Cancer Metastatic
Register for Updates
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: City of Hope, Duarte, California +60 locations
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
Register for Updates
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT03821246
Recruiting
This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by prostate cancer and within the tumor microenv... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
Register for Updates
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697
Recruiting
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri +11 locations
Conditions: Prostate Cancer
Register for Updates
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT06673329
Recruiting
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Register for Updates
Active Surveillance for Cancer of the Prostate (ASCaP)
NCT00949819
Recruiting
Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.
Gender:
MALE
Ages:
Between 30 years and 85 years
Trial Updated:
05/09/2025
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Prostate Cancer
Register for Updates